$KITE News Options remain limited for growth-s
Post# of 144482
Posted On: 01/28/2015 12:06:16 PM
$KITE News
Options remain limited for growth-stock speculators 3:17 p.m. Jan. 22, 2015 - The Trading Deck
Some of the Nasdaq’s leading lights have begun to dim 2:03 p.m. Jan. 15, 2015 - The Trading Deck
Leading growth stocks continue to shine 3:08 p.m. Jan. 13, 2015 - The Trading Deck
6 stocks to watch 9:22 a.m. Jan. 8, 2015 - The Trading Deck
Amgen and Kite Pharma in cancer immunotherapy pact 10:01 a.m. Jan. 5, 2015 - Tess Stynes
S&P 500 ends higher for first-ever close above 2,000 3:32 p.m. Aug. 26, 2014 - Victor Reklaitis
Google buys Zync; Mobileye rallies, Orbitz falls 2:34 p.m. Aug. 26, 2014 - Angela Johnson
Kite Pharma shares fly high on study results 4:47 p.m. Aug. 25, 2014 - Wallace Witkowski
Kite Pharma shares surge 49% on drug study result 3:50 p.m. Aug. 25, 2014 - Wallace Witkowski
Advaxis: Legit Reasons to Take Another Look at Under-Appreciated Cancer Immunotherapy 9:53 a.m. Jan. 27, 2015 - TheStreet.com
Can CAR-T Therapy Live Up To The Biotech IPO Hype? 7:02 a.m. Jan. 26, 2015 - Investors Business Daily
Kite Pharma (KITE) in Focus: Stock Tumbles 9.2% - Tale of the Tape 8:56 a.m. Jan. 22, 2015 - Zacks.com
CAR-T Vs ErbB3 Market Opportunity Comparison 1:32 p.m. Jan. 21, 2015 - Seeking Alpha
Advaxis: Heavily Promoted And Misleading Investors 9:30 a.m. Jan. 21, 2015 - Seeking Alpha
Why Wynn Resorts, SAP and Kite Pharma Are 3 of Today’s Worst Stocks 10:49 a.m. Jan. 20, 2015 - InvestorPlace.com
8 Biotech Stock Controversies Emerging From 'JPM15' Conference 10:18 a.m. Jan. 20, 2015 - TheStreet.com
The Week That Was: Healthcare Outlook Remains Excellent 9:44 a.m. Jan. 20, 2015 - Seeking Alpha
Investments for the Long Term 8:38 p.m. Jan. 17, 2015 - The Wall Street Journal Interactive Edition
ZIOPHARM, Intrexon Ink CAR T Deal with MD Anderson - Analyst Blog 4:45 p.m. Jan. 16, 2015 - Zacks.com
Kite Pharma/Amgen: A Strong Combination 1:19 p.m. Jan. 15, 2015 - Seeking Alpha
Ziopharm up big on CAR-T license deal 8:25 a.m. Jan. 14, 2015 - Seeking Alpha
Value Investing Strategy For Biotech 12:57 p.m. Jan. 12, 2015 - Seeking Alpha
Seeking Alpha's Biotech Weekly: Gilead Rises With Phenex, Bass's Patent Attack, And More 4:00 p.m. Jan. 9, 2015 - Seeking Alpha
Mizuho Securities Initiates Kite Pharma With Buy 7:40 a.m. Jan. 9, 2015 - benzinga.com
I-Bankers Look At Another Huge Year for IPOs 8:30 a.m. Jan. 8, 2015 - InvestorPlace.com
Kite Pharma inks deal with NIH in HPV-related cancer 1:28 p.m. Jan. 7, 2015 - Seeking Alpha
Pharmaceutical Companies Amgen and Kite Partner for Cancer Therapy 12:18 p.m. Jan. 7, 2015 - GuruFocus.com
Biotech Stock Roundup: Kite Flies High on Amgen Deal, Isis Soars on J&J Collaboration - Analyst Blog 9:09 a.m. Jan. 7, 2015 - Zacks.com
Kite Pharma Up on Amgen Cancer Immunotherapy Tie-Up - Analyst Blog 7:00 p.m. Jan. 6, 2015 - Zacks.com
Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy 8:01 a.m. Jan. 22, 2015 - GlobeNewswire
Kite Pharma Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process 3:00 p.m. Jan. 19, 2015 - GlobeNewswire
Today's Review on Biotech Equities - Kite Pharma, Organovo Holdings, BioMarin Pharma, NephroGenex, and Neuralstem 9:15 a.m. Jan. 9, 2015 - PR Newswire - PRF
Kite Pharma Expands Senior Management Team With Appointment of Claudine Prowse, Ph.D., as SVP, Corporate Communications and Investor Relations 8:01 a.m. Jan. 9, 2015 - GlobeNewswire
Kite Pharma Announces Addition of Scott N. Bernstein as Vice President of Intellectual Property Law 5:14 p.m. Jan. 8, 2015 - GlobeNewswire
Kite Pharma Announces Exclusive License With the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat HPV-Associated Cancers 1:00 p.m. Jan. 7, 2015 - GlobeNewswire
Kite Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference 8:01 a.m. Jan. 7, 2015 - GlobeNewswire
Scaling New Heights: Complimentary Research on Stereotaxis, Kite Pharma, ISIS Pharma, Merck and General Motors 8:50 a.m. Jan. 6, 2015 - PR Newswire - PRF
Kite Pharma Granted Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy 8:01 a.m. Jan. 6, 2015 - GlobeNewswire
Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies 9:00 a.m. Jan. 5, 2015 - PR Newswire - PRF
Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 8:31 a.m. Dec. 30, 2014 - GlobeNewswire
Kite Pharma Submits Investigational New Drug Application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, for the Treatment of Refractory Aggressive Non-Hodgkin Lymphoma 12:40 p.m. Dec. 22, 2014 - GlobeNewswire
Kite Pharma Added to the NASDAQ Biotechnology Index 8:01 a.m. Dec. 16, 2014 - GlobeNewswire
Annual Changes to the NASDAQ Biotechnology Index 7:10 a.m. Dec. 15, 2014 - GlobeNewswire
Kite Pharma Announces Pricing of Follow-On Offering 9:00 p.m. Dec. 10, 2014 - GlobeNewswire
BioPharm Insight Releases Hematological Cancer Report in Advance of American Society of Hematology (ASH) Annual Meeting Next Month 2:19 p.m. Nov. 24, 2014 - BusinessWire - BZX
Kite Pharma Announces Presentations at the Upcoming 56th American Society of Hematology Annual Meeting 8:01 a.m. Nov. 18, 2014 - GlobeNewswire
Could This Emerging Drug Developer Really Be Worth A Billion Dollars In Five Years? 8:02 a.m. Nov. 17, 2014 - ACCESSWIRE
Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Investigational Cancer Immunotherapy 8:01 a.m. Nov. 17, 2014 - GlobeNewswire
Kite Pharma Reports Third Quarter 2014 Results 3:20 p.m. Nov. 14, 2014 - GlobeNewswire
Options remain limited for growth-stock speculators 3:17 p.m. Jan. 22, 2015 - The Trading Deck
Some of the Nasdaq’s leading lights have begun to dim 2:03 p.m. Jan. 15, 2015 - The Trading Deck
Leading growth stocks continue to shine 3:08 p.m. Jan. 13, 2015 - The Trading Deck
6 stocks to watch 9:22 a.m. Jan. 8, 2015 - The Trading Deck
Amgen and Kite Pharma in cancer immunotherapy pact 10:01 a.m. Jan. 5, 2015 - Tess Stynes
S&P 500 ends higher for first-ever close above 2,000 3:32 p.m. Aug. 26, 2014 - Victor Reklaitis
Google buys Zync; Mobileye rallies, Orbitz falls 2:34 p.m. Aug. 26, 2014 - Angela Johnson
Kite Pharma shares fly high on study results 4:47 p.m. Aug. 25, 2014 - Wallace Witkowski
Kite Pharma shares surge 49% on drug study result 3:50 p.m. Aug. 25, 2014 - Wallace Witkowski
Advaxis: Legit Reasons to Take Another Look at Under-Appreciated Cancer Immunotherapy 9:53 a.m. Jan. 27, 2015 - TheStreet.com
Can CAR-T Therapy Live Up To The Biotech IPO Hype? 7:02 a.m. Jan. 26, 2015 - Investors Business Daily
Kite Pharma (KITE) in Focus: Stock Tumbles 9.2% - Tale of the Tape 8:56 a.m. Jan. 22, 2015 - Zacks.com
CAR-T Vs ErbB3 Market Opportunity Comparison 1:32 p.m. Jan. 21, 2015 - Seeking Alpha
Advaxis: Heavily Promoted And Misleading Investors 9:30 a.m. Jan. 21, 2015 - Seeking Alpha
Why Wynn Resorts, SAP and Kite Pharma Are 3 of Today’s Worst Stocks 10:49 a.m. Jan. 20, 2015 - InvestorPlace.com
8 Biotech Stock Controversies Emerging From 'JPM15' Conference 10:18 a.m. Jan. 20, 2015 - TheStreet.com
The Week That Was: Healthcare Outlook Remains Excellent 9:44 a.m. Jan. 20, 2015 - Seeking Alpha
Investments for the Long Term 8:38 p.m. Jan. 17, 2015 - The Wall Street Journal Interactive Edition
ZIOPHARM, Intrexon Ink CAR T Deal with MD Anderson - Analyst Blog 4:45 p.m. Jan. 16, 2015 - Zacks.com
Kite Pharma/Amgen: A Strong Combination 1:19 p.m. Jan. 15, 2015 - Seeking Alpha
Ziopharm up big on CAR-T license deal 8:25 a.m. Jan. 14, 2015 - Seeking Alpha
Value Investing Strategy For Biotech 12:57 p.m. Jan. 12, 2015 - Seeking Alpha
Seeking Alpha's Biotech Weekly: Gilead Rises With Phenex, Bass's Patent Attack, And More 4:00 p.m. Jan. 9, 2015 - Seeking Alpha
Mizuho Securities Initiates Kite Pharma With Buy 7:40 a.m. Jan. 9, 2015 - benzinga.com
I-Bankers Look At Another Huge Year for IPOs 8:30 a.m. Jan. 8, 2015 - InvestorPlace.com
Kite Pharma inks deal with NIH in HPV-related cancer 1:28 p.m. Jan. 7, 2015 - Seeking Alpha
Pharmaceutical Companies Amgen and Kite Partner for Cancer Therapy 12:18 p.m. Jan. 7, 2015 - GuruFocus.com
Biotech Stock Roundup: Kite Flies High on Amgen Deal, Isis Soars on J&J Collaboration - Analyst Blog 9:09 a.m. Jan. 7, 2015 - Zacks.com
Kite Pharma Up on Amgen Cancer Immunotherapy Tie-Up - Analyst Blog 7:00 p.m. Jan. 6, 2015 - Zacks.com
Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy 8:01 a.m. Jan. 22, 2015 - GlobeNewswire
Kite Pharma Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process 3:00 p.m. Jan. 19, 2015 - GlobeNewswire
Today's Review on Biotech Equities - Kite Pharma, Organovo Holdings, BioMarin Pharma, NephroGenex, and Neuralstem 9:15 a.m. Jan. 9, 2015 - PR Newswire - PRF
Kite Pharma Expands Senior Management Team With Appointment of Claudine Prowse, Ph.D., as SVP, Corporate Communications and Investor Relations 8:01 a.m. Jan. 9, 2015 - GlobeNewswire
Kite Pharma Announces Addition of Scott N. Bernstein as Vice President of Intellectual Property Law 5:14 p.m. Jan. 8, 2015 - GlobeNewswire
Kite Pharma Announces Exclusive License With the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat HPV-Associated Cancers 1:00 p.m. Jan. 7, 2015 - GlobeNewswire
Kite Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference 8:01 a.m. Jan. 7, 2015 - GlobeNewswire
Scaling New Heights: Complimentary Research on Stereotaxis, Kite Pharma, ISIS Pharma, Merck and General Motors 8:50 a.m. Jan. 6, 2015 - PR Newswire - PRF
Kite Pharma Granted Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy 8:01 a.m. Jan. 6, 2015 - GlobeNewswire
Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies 9:00 a.m. Jan. 5, 2015 - PR Newswire - PRF
Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 8:31 a.m. Dec. 30, 2014 - GlobeNewswire
Kite Pharma Submits Investigational New Drug Application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, for the Treatment of Refractory Aggressive Non-Hodgkin Lymphoma 12:40 p.m. Dec. 22, 2014 - GlobeNewswire
Kite Pharma Added to the NASDAQ Biotechnology Index 8:01 a.m. Dec. 16, 2014 - GlobeNewswire
Annual Changes to the NASDAQ Biotechnology Index 7:10 a.m. Dec. 15, 2014 - GlobeNewswire
Kite Pharma Announces Pricing of Follow-On Offering 9:00 p.m. Dec. 10, 2014 - GlobeNewswire
BioPharm Insight Releases Hematological Cancer Report in Advance of American Society of Hematology (ASH) Annual Meeting Next Month 2:19 p.m. Nov. 24, 2014 - BusinessWire - BZX
Kite Pharma Announces Presentations at the Upcoming 56th American Society of Hematology Annual Meeting 8:01 a.m. Nov. 18, 2014 - GlobeNewswire
Could This Emerging Drug Developer Really Be Worth A Billion Dollars In Five Years? 8:02 a.m. Nov. 17, 2014 - ACCESSWIRE
Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Investigational Cancer Immunotherapy 8:01 a.m. Nov. 17, 2014 - GlobeNewswire
Kite Pharma Reports Third Quarter 2014 Results 3:20 p.m. Nov. 14, 2014 - GlobeNewswire
(0)
(0)Scroll down for more posts ▼